Professor Owe Orwar, CEO of Oblique Therapeutics will make the first public disclosure of the company´s transformative platform for for functional antibody discovery and design at the 3rd Drug Discovery Innovation Programme 5-6 Oct 2017 Munich, Germany.
Short non-confidential presentation of Oblique Theraputics by Carolina Trkulja, CSO in Swedish with English text.
Oblique Therapeutics has received a grant from the Vinnova future biological medicines program to develop functional antibodies against TRPV1 and TRPV2 for inflammatory/idiopathic pain and metastatic cancer, respectively.
Oblique Therapeutics has entered into a discovery agreement with a global leader in diabetes medicines and care regarding the development of two functional antibodies against type 2 diabetes targets.
Oblique Therapeutics has in-licensed novel undisclosed anticancer agents from NIH and Karolinska Institutet
Oblique Therapeutics has in-licensed three chemical series of novel undisclosed anticancer agents from the US National Institute of Health and the Karolinska Institute in Stockholm, Sweden.